A RARE CASE AND AN EFFECTIVE DRUG THERAPY: OFF-LABEL USE OF TACROLIMUS IN A PAEDIATRIC DYSIMMUNE DISEASE
4CPS-155
COMPARATIVE STUDY FOR EVALUATION OF THE PAIN, EASE OF USE AND PREFERENCE BETWEEN TWO ADALIMUMAB ADMINISTRATION DEVICES: STUDY ADAP2017
4CPS-154
FOLLOW-UP IN THE USE OF BIOTHERAPIES IN CROHN’S DISEASE IN A FRENCH UNIVERSITY HOSPITAL
4CPS-152
ECULIZUMAB FOR DENSE DEPOSIT DISEASE: INCREASED DOSAGE WITHOUT RESPONSE: A CASE REPORT
4CPS-151
OPTIMISATION PROGRAMME OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS: RESULTS OF CREATE REGISTRY AFTER 3 YEARS
4CPS-138
QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS WITH PARENTERAL FIRST-LINE TREATMENT: EXPERIENCE IN A UNIVERSITY HOSPITAL
4CPS-136
ARE CARDIOVASCULAR ADVERSE EVENTS WITH IBRUTINIB WELL CONSIDERED?
4CPS-135
EFFECTIVENESS AND COST OF ECULIZUMAB ON PATIENTS WITH ATYPICAL (SHUA), URENIC AND HAEMOLITIC SYNDROME, WITH ENLARGEMENT OF THE FREQUENCY OF ADMINISTRATION
4CPS-129
EVALUATION OF THE REAL INFUSION TIME OF INTRAVENOUS IMMUNOGLOBULIN AND INFLUENTIAL FACTORS IN ROUTINE CLINICAL PRACTICE ANALYSIS
4CPS-116
ALECTINIB HEPATIC-TOLERANCE IN PATIENTS WITH HEPATOTOXICITY BACKGROUND WITH OTHER ANAPLASTIC LYMPHOMA KINASE (ALK)-INHIBITORS
4CPS-112
SYNOPTIC TABLE OF RELEVANT DRUG INTERACTIONS TO BE USED AS CLINICAL DECISION SUPPORT TOOL ON HAEMATO-ONCOLOGY WARDS
4CPS-105
BLINATUMOMAB FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN A PAEDIATRIC PATIENT: A CASE REPORT
4CPS-097
EXTENDED VERSUS STANDARD CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANTATION
4CPS-091
VARIATION OF THE HIV-NAÏVE PATIENT PROFILE AND INITIAL ART RECOMMENDED REGIMENS AFTER IMPLEMENTATION OF THE UNIVERSAL TREATMENT RECOMMENDATIONS IN A UNIVERSITY HOSPITAL
4CPS-089
ALL-ORAL DIRECT-ACTING ANTIVIRAL COMBINATION THERAPY: CHRONIC HEPATITIS C TREATMENT AFTER UNSUCCESSFUL THERAPY WITH DAAs AGENTS
